Aldeyra Therapeutics, Inc.

8-K Entered a material agreement Jul 30, 2026 8-K Other events Jul 15, 2026 8-K Director or officer change; Shareholder vote results; Regulation FD disclosure Jun 10, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Regulation FD disclosure May 1, 2026 8-K Director or officer change Apr 20, 2026 8-K Other events Apr 1, 2026 8-K Regulation FD disclosure; Other events Mar 17, 2026 10-K Fiscal year ended 2025-12-31 Feb 27, 2026 8-K Director or officer change Dec 31, 2025 8-K Regulation FD disclosure; Other events Dec 16, 2025 8-K Regulation FD disclosure; Other events Nov 13, 2025 10-Q Quarter ended 2025-09-30 Nov 5, 2025 8-K Other events Oct 28, 2025 8-K Aug 19, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Other events Jul 17, 2025 8-K Regulation FD disclosure; Other events Jun 26, 2025 8-K Other events Jun 17, 2025 8-K Shareholder vote results Jun 11, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Regulation FD disclosure; Other events May 6, 2025 8-K Director or officer change Apr 17, 2025 8-K Regulation FD disclosure; Other events Apr 3, 2025 10-K/A Fiscal year ended 2024-12-31 Mar 28, 2025 10-K Fiscal year ended 2024-12-31 Feb 28, 2025 8-K Entered a material agreement; Other events Nov 18, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Other events Oct 3, 2024 8-K Entered a material agreement; Took on a direct financial obligation Oct 2, 2024 8-K Director or officer change Sep 3, 2024 8-K Regulation FD disclosure; Other events Aug 8, 2024 8-K Entered a material agreement Aug 1, 2024 10-Q Quarter ended 2024-06-30 Aug 1, 2024 8-K Other events Jun 20, 2024 8-K Regulation FD disclosure Jun 13, 2024 8-K Shareholder vote results Jun 7, 2024 10-Q Quarter ended 2024-03-31 May 2, 2024 8-K Regulation FD disclosure; Other events Apr 25, 2024 8-K Regulation FD disclosure Mar 28, 2024